Thalia A. Farazi

5.0k citations

39 papers · 3.7k indexed · 2 hit papers · h-index 22

Cancer Research top 0.5%
- MicroRNA in disease regulation 9
- Cancer-related molecular mechanisms research 6
Molecular Biology top 2%
- RNA modifications and cancer 6
- Protein Kinase Regulation and GTPase Signaling 5
Genetics top 5%
- Chronic Lymphocytic Leukemia Research 6
Oncology top 10%
- CAR-T cell therapy research 14
Cell Biology top 5%
Pathology and Forensic Medicine
- Lymphoma Diagnosis and Treatment 9
Materials Chemistry
- Enzyme Structure and Function 6

Co-authors: Thomas Tuschl Pavel Morozov Jeffrey I. Gordon Gabriel Waksman Jessica I. Hoell Stefan Juranek Markus Hafner Aleksandra Mihailović
Cited by: Cancer Research Molecular Biology Genetics
Journals: Nucleic Acids Research (1 paper)Journal of Biological Chemistry (3 papers)Journal of Clinical Oncology (3 papers)
Partner nations: United States Switzerland Netherlands

In The Last Decade

Thalia A. Farazi

37 papers receiving 3.6k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Thalia A. Farazi

Since Specialization

Citations

This map shows the geographic impact of Thalia A. Farazi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thalia A. Farazi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thalia A. Farazi more than expected).

Fields of papers citing papers by Thalia A. Farazi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thalia A. Farazi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thalia A. Farazi. The network helps show where Thalia A. Farazi may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Thalia A. Farazi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Thalia A. Farazi Line = papers co-authored together Thalia A. Farazi links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Matching-adjusted indirect comparison of efficacy and safety of lisocabtagene maraleucel and mosunetuzumab for the treatment of third-line or later relapsed or refractory follicular lymphoma Experimental Hematology and Oncology ·Loretta J. Nastoupil,Ashley Bonner,Pearl Wang,Lamees Almuallem,Jigar Desai,Thalia A. Farazi,Jinender Kumar,Saurabh Dahiya	2025	1
2	A Systematic Literature Review (SLR) and Meta-Analysis of Clinical Evidence of Second Line or Later (2L+) Treatments for Follicular Lymphoma (FL) in Adult Patients Blood ·Samantha Craigie,Abril Oliva Ramirez,Emily Rosta,Jigar Desai,Omotayo Fasan,Thalia A. Farazi,Jinender Kumar	2023	1
3	Matching-Adjusted Indirect Comparison (MAIC) of Efficacy and Safety of Lisocabtagene Maraleucel (liso-cel) and Mosunetuzumab for the Treatment (Tx) of Third Line or Later (3L+) Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Blood ·Loretta J. Nastoupil,Ashley Bonner,Pearl Wang,Lamees Almuallem,Jigar Desai,Omotayo Fasan,Thalia A. Farazi,Jinender Kumar,Saurabh Dahiya	2023	5
4	Lisocabtagene maraleucel (liso-cel) treatment of patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) and secondary CNS lymphoma: Initial results from TRANSCEND NHL 001. Journal of Clinical Oncology ·Jeremy S. Abramson,Maria Lia Palomba,Jon Arnason,Matthew A. Lunning,Scott R. Solomon,Thalia A. Farazi,Jacob Garcia,Benhuai Xie,Kathryn J. Newhall,Christine Dehner,Tanya Siddiqi	2019	13
5	Accelerating Drug Development in Pediatric Cancer: A Novel Phase I Study Design of Venetoclax in Relapsed/Refractory Malignancies Future Oncology ·Andrew E. Place,Kelly C. Goldsmith,Jean‐Pierre Bourquin,Mignon L. Loh,Lia Gore,Daniel A. Morgenstern,Yeshwant D. Sanzgiri,David Hoffman,Ying Zhou,Jeremy A. Ross,Betty Prine,Mohamad Shebley,Megan McNamee,Thalia A. Farazi,Su Young Kim,Maria Verdugo,L. Leanne Lash-Fleming,C. Michel Zwaan,Josef Vormoor	2018	39
6	A Simulation Analysis to Evaluate the Effect of Prospective Biomarker Testing on Progression-Free Survival (PFS) in DLBCL Blood ·Edith Szafer‐Glusman,Juan Liu,Franklin Peale,Thalia A. Farazi,Jill Ray,Carsten Horn,Mikkel Z. Oestergaard,Martin Kornacker,Laurie H. Sehn,Günter Fingerle‐Rowson,Jeffrey M. Venstrom,Michelle Byrtek,Elizabeth A. Punnoose	2017	1
7	BCL2 Expression Identifies a Population with Unmet Medical Need in Previously Untreated (1L) Patients with DLBCL Blood ·Edith Szafer‐Glusman,Franklin Peale,Guiyuan Lei,Anja Mottok,Pedro Farinha,Jill Ray,Thalia A. Farazi,Martin Kornacker,Mikkel Z. Oestergaard,Juan Liu,Randy D. Gascoyne,Elizabeth A. Punnoose	2017	1
8	Structural basis underlying CAC RNA recognition by the RRM domain of dimeric RNA-binding protein RBPMS Quarterly Reviews of Biophysics ·Marianna Teplova,Thalia A. Farazi,Thomas Tuschl,Dinshaw J. Patel	2015	41
9	Identification of the RNA recognition element of the RBPMS family of RNA-binding proteins and their transcriptome-wide mRNA targets RNA ·Thalia A. Farazi,Carl-Stephan Leonhardt,Neelanjan Mukherjee,Aleksandra Mihailović,Song Li,Klaas E.A. Max,Cindy Meyer,Masashi Yamaji,Pavol Čekan,Nicholas C. Jacobs,Stefanie Gerstberger,Claudia Bognanni,Erik Larsson,Uwe Ohler,Thomas Tuschl	2014	43
10	PAR-CLIP (Photoactivatable Ribonucleoside-Enhanced Crosslinking and Immunoprecipitation) Methods in enzymology on CD-ROM/Methods in enzymology ·Jessica Spitzer,Markus Hafner,Markus Landthaler,Manuel Ascano,Thalia A. Farazi,Greg Wardle,Jeff Nusbaum,Mohsen Khorshid,Lukas Burger,Mihaela Zavolan,Thomas Tuschl	2014	76
11	Mammalian miRNA curation through next-generation sequencing Frontiers in Genetics ·Miguel Brown,Hemant Suryawanshi,Markus Hafner,Thalia A. Farazi,Thomas Tuschl	2013	35
12	An Arrayed RNA Interference Genome-Wide Screen Identifies Candidate Genes Involved in the MicroRNA 21 Biogenesis Pathway Assay and Drug Development Technologies ·David Shum,Bhavneet Bhinder,Christina N. Ramirez,Constantin Radu,Paul Calder,Lesslie Beauchamp,Thalia A. Farazi,Markus Landthaler,T. Tuschi,Susan Magdaleno,Hakim Djaballah	2012	5
13	Barcoded cDNA library preparation for small RNA profiling by next-generation sequencing Methods ·Markus Hafner,Neil Renwick,Thalia A. Farazi,Aleksandra Mihailović,John Pena,Thomas Tuschl	2012	92
14	MicroRNAs in Human Cancerbreakdown → Advances in experimental medicine and biology ·Thalia A. Farazi,Jessica I. Hoell,Pavel Morozov,Thomas Tuschl	2012	598
15	Bioinformatic analysis of barcoded cDNA libraries for small RNA profiling by next-generation sequencing Methods ·Thalia A. Farazi,Miguel Brown,Pavel Morozov,Jelle J. ten Hoeve,Iddo Z. Ben‐Dov,Volker Hovestadt,Markus Hafner,Neil Renwick,Aleksandra Mihailović,Lodewyk F.A. Wessels,Thomas Tuschl	2012	57
16	MicroRNA Sequence and Expression Analysis in Breast Tumors by Deep Sequencing Cancer Research ·Thalia A. Farazi,Hugo M. Horlings,Jelle J. ten Hoeve,Aleksandra Mihailović,Hans Halfwerk,Pavel Morozov,Miguel Brown,Markus Hafner,Fabien Reyal,Marieke van Kouwenhove,Bas Kreike,Daoud Sie,Volker Hovestadt,Lodewyk F.A. Wessels,Marc J. van de Vijver,Thomas Tuschl	2011	275
17	RNA targets of wild-type and mutant FET family proteins Nature Structural & Molecular Biology ·Jessica I. Hoell,Erik Larsson,Simon Runge,Jeffrey D. Nusbaum,Sujitha Duggimpudi,Thalia A. Farazi,Markus Hafner,Arndt Borkhardt,Chris Sander,Thomas Tuschl	2011	282
18	The Biology and Enzymology of ProteinN-Myristoylation Journal of Biological Chemistry ·Thalia A. Farazi,Gabriel Waksman,Jeffrey I. Gordon	2001	437
19	A Role for Saccharomyces cerevisiae Fatty Acid Activation Protein 4 in Regulating ProteinN-Myristoylation during Entry into Stationary Phase Journal of Biological Chemistry ·Kaveh Ashrafi,Thalia A. Farazi,Jeffrey I. Gordon	1998	85
20	Structure of N-myristoyltransferase with bound myristoylCoA and peptide substrate analogs Nature Structural Biology ·Rajiv S. Bhatnagar,Klaus Fütterer,Thalia A. Farazi,Sergey Korolev,Clare L. Murray,Emily Jackson-Machelski,George W. Gokel,Jeffrey I. Gordon,Gabriel Waksman	1998	109

About Thalia A. Farazi

Thalia A. Farazi is a scholar working on Genetics, Cancer Research and Oncology, having authored 39 papers that have together received 3.7k indexed citations. Recurring topics across this work include CAR-T cell therapy research (14 papers), MicroRNA in disease regulation (9 papers), Lymphoma Diagnosis and Treatment (9 papers), Chronic Lymphocytic Leukemia Research (6 papers), RNA modifications and cancer (6 papers), Cancer-related molecular mechanisms research (6 papers), Enzyme Structure and Function (6 papers) and Protein Kinase Regulation and GTPase Signaling (5 papers). The work is most often cited by research in Cancer Research (1.8k citations), Molecular Biology (3.0k citations) and Genetics (163 citations). Thalia A. Farazi has collaborated with scholars based in United States, Switzerland and Netherlands. Frequent co-authors include Thomas Tuschl, Pavel Morozov, Jeffrey I. Gordon, Gabriel Waksman, Jessica I. Hoell, Stefan Juranek, Markus Hafner, Aleksandra Mihailović, Miguel Brown and Erik Larsson. Their work appears in journals such as Nucleic Acids Research, Journal of Biological Chemistry and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact